Minnesota 2025-2026 Regular Session

Minnesota Senate Bill SF1054 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1		1.1 A bill for an act
2	2		1.2 relating to health insurance; requiring coverage of vasectomies by health plans;
3		-	1.3 requiring the medical assistance program and MinnesotaCare to cover vasectomies;
4		-	1.4 amending Minnesota Statutes 2024, sections 62Q.522, subdivision 1; 256B.0625,
5		-	1.5 by adding a subdivision.
6		-	1.6BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
7		-	1.7 Section 1. Minnesota Statutes 2024, section 62Q.522, subdivision 1, is amended to read:
8		-	1.8 Subdivision 1.Definitions.(a) The definitions in this subdivision apply to this section.
9		-	1.9 (b) "Contraceptive method" means a drug, device, or other product approved by the
10		-	1.10Food and Drug Administration to prevent unintended pregnancy.
11		-	1.11 (c) "Contraceptive service" means consultation, examination, procedures, and medical
12		-	1.12services related to the prevention of unintended pregnancy, excluding vasectomies. This
13		-	1.13includes but is not limited to voluntary sterilization procedures, patient education, counseling
14		-	1.14on contraceptives, and follow-up services related to contraceptive methods or services,
15		-	1.15management of side effects, counseling for continued adherence, and device insertion or
16		-	1.16removal.
17		-	1.17 (d) "Medical necessity" includes but is not limited to considerations such as severity of
18		-	1.18side effects, difference in permanence and reversibility of a contraceptive method or service,
19		-	1.19and ability to adhere to the appropriate use of the contraceptive method or service, as
20		-	1.20determined by the attending provider.
21		-	1.21 (e) "Therapeutic equivalent version" means a drug, device, or product that can be expected
22		-	1.22to have the same clinical effect and safety profile when administered to a patient under the
23		-	1.23conditions specified in the labeling, and that:
	3	+	1.3 amending Minnesota Statutes 2024, section 62Q.522, subdivision 1.
	4	+	1.4BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
	5	+	1.5 Section 1. Minnesota Statutes 2024, section 62Q.522, subdivision 1, is amended to read:
	6	+	1.6 Subdivision 1.Definitions.(a) The definitions in this subdivision apply to this section.
	7	+	1.7 (b) "Contraceptive method" means a drug, device, or other product approved by the
	8	+	1.8Food and Drug Administration to prevent unintended pregnancy.
	9	+	1.9 (c) "Contraceptive service" means consultation, examination, procedures, and medical
	10	+	1.10services related to the prevention of unintended pregnancy, excluding vasectomies. This
	11	+	1.11includes but is not limited to voluntary sterilization procedures, patient education, counseling
	12	+	1.12on contraceptives, and follow-up services related to contraceptive methods or services,
	13	+	1.13management of side effects, counseling for continued adherence, and device insertion or
	14	+	1.14removal.
	15	+	1.15 (d) "Medical necessity" includes but is not limited to considerations such as severity of
	16	+	1.16side effects, difference in permanence and reversibility of a contraceptive method or service,
	17	+	1.17and ability to adhere to the appropriate use of the contraceptive method or service, as
	18	+	1.18determined by the attending provider.
	19	+	1.19 (e) "Therapeutic equivalent version" means a drug, device, or product that can be expected
	20	+	1.20to have the same clinical effect and safety profile when administered to a patient under the
	21	+	1.21conditions specified in the labeling, and that:
	22	+	1.22 (1) is approved as safe and effective;
24	23		1Section 1.
25		-	~~S1054-1 1st Engrossment~~~~SF1054~~ REVISOR RSI
	24	+	25-01345 as introduced12/19/24 REVISOR RSI/NS
26	25		SENATE
27	26		STATE OF MINNESOTA
28	27		S.F. No. 1054NINETY-FOURTH SESSION
29		-	(SENATE AUTHORS: MANN, Abeler, Maye Quade and Wiklund)
	28	+	(SENATE AUTHORS: MANN, Abeler, Lieske, Maye Quade and Wiklund)
30	29		OFFICIAL STATUSD-PGDATE
31		-	Introduction and first reading30202/06/2025
32		-	Referred to Commerce and Consumer Protection
33		-	Author stricken Lieske62603/03/2025
34		-	Comm report: To pass as amended and re-refer to Health and Human Services03/10/2025 2.1 (1) is approved as safe and effective;
35		-	2.2 (2) is a pharmaceutical equivalent: (i) containing identical amounts of the same active
36		-	2.3drug ingredient in the same dosage form and route of administration; and (ii) meeting
37		-	2.4compendial or other applicable standards of strength, quality, purity, and identity;
38		-	2.5 (3) is bioequivalent in that:
39		-	2.6 (i) the drug, device, or product does not present a known or potential bioequivalence
40		-	2.7problem and meets an acceptable in vitro standard; or
41		-	2.8 (ii) if the drug, device, or product does present a known or potential bioequivalence
42		-	2.9problem, it is shown to meet an appropriate bioequivalence standard;
43		-	2.10 (4) is adequately labeled; and
44		-	2.11 (5) is manufactured in compliance with current manufacturing practice regulations.
45		-	2.12 EFFECTIVE DATE.This section is effective January 1, 2026, and applies to health
46		-	2.13plans offered, issued, or renewed on or after that date.
47		-	2.14 Sec. 2. Minnesota Statutes 2024, section 256B.0625, is amended by adding a subdivision
48		-	2.15to read:
49		-	2.16 Subd. 77.Vasectomies.(a) Medical assistance covers vasectomies.
50		-	2.17 (b) Medical assistance must meet the requirements with respect to coverage of
51		-	2.18vasectomies that would otherwise apply to a health plan under section 62Q.522, except that
52		-	2.19medical assistance is not required to comply with any provision of section 62Q.522 if
53		-	2.20compliance with the provision would:
54		-	2.21 (1) prevent the state from receiving federal financial participation for the coverage under
55		-	2.22this subdivision;
56		-	2.23 (2) result in a lower level of coverage or reduced access to coverage for medical assistance
57		-	2.24enrollees; or
58		-	2.25 (3) violate Code of Federal Regulations, title 42, part 441, subpart F.
59		-	2.26 EFFECTIVE DATE.This section is effective January 1, 2026, or upon federal approval,
60		-	2.27whichever is later. The commissioner of human services shall notify the revisor of statutes
61		-	2.28when federal approval is obtained.
62		-	2Sec. 2.
63		-	S1054-1 1st EngrossmentSF1054 REVISOR RSI
	30	+	Introduction and first reading02/06/2025
	31	+	Referred to Commerce and Consumer Protection 2.1 (2) is a pharmaceutical equivalent: (i) containing identical amounts of the same active
	32	+	2.2drug ingredient in the same dosage form and route of administration; and (ii) meeting
	33	+	2.3compendial or other applicable standards of strength, quality, purity, and identity;
	34	+	2.4 (3) is bioequivalent in that:
	35	+	2.5 (i) the drug, device, or product does not present a known or potential bioequivalence
	36	+	2.6problem and meets an acceptable in vitro standard; or
	37	+	2.7 (ii) if the drug, device, or product does present a known or potential bioequivalence
	38	+	2.8problem, it is shown to meet an appropriate bioequivalence standard;
	39	+	2.9 (4) is adequately labeled; and
	40	+	2.10 (5) is manufactured in compliance with current manufacturing practice regulations.
	41	+	2.11 EFFECTIVE DATE.This section is effective January 1, 2026, and applies to health
	42	+	2.12plans offered, issued, or renewed on or after that date.
	43	+	2Section 1.
	44	+	25-01345 as introduced12/19/24 REVISOR RSI/NS